Alerts will be sent to your verified email
Verify Email
JENBURPH
|
Jenburkt Pharma
|
Kilitch Drugs(India)
|
Prevest Denpro
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
0.29 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
18.49 % | 7.31 % | 19.0 % |
|
5yr average Equity Multiplier
|
1.17 | 1.48 | 1.07 |
|
5yr Average Asset Turnover Ratio
|
0.88 | 0.56 | 0.6 |
|
5yr Avg Net Profit Margin
|
18.1 % | 8.44 % | 29.64 % |
|
Price to Book
|
2.61 | 1.96 | 4.36 |
|
P/E
|
14.81 | 19.95 | 25.45 |
|
5yr Avg Cash Conversion Cycle
|
-32.02 Days | 14.76 Days | 42.6 Days |
|
Inventory Days
|
24.72 Days | 14.42 Days | 36.0 Days |
|
Days Receivable
|
48.38 Days | 136.16 Days | 44.41 Days |
|
Days Payable
|
82.6 Days | 212.73 Days | 39.32 Days |
|
5yr Average Interest Coverage Ratio
|
87.2 | 6.02 | 99.71 |
|
5yr Avg ROCE
|
24.44 % | 11.26 % | 25.39 % |
|
5yr Avg Operating Profit Margin
|
22.46 % | 12.28 % | 36.91 % |
|
5 yr average Debt to Equity
|
0.02 | 0.17 | 0.0 |
|
5yr CAGR Net Profit
|
14.21 % | 48.72 % | 2.94 % |
|
5yr Average Return on Assets
|
15.8 % | 4.99 % | 17.71 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
46.64 % | 63.77 % | 73.6 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.92 % | -4.48 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Jenburkt Pharma
|
Kilitch Drugs(India)
|
Prevest Denpro
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|